Foresite Capital Management III’s Aclaris Therapeutics ACRS Stock Holding History

Foresite Capital Management III’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,954,904	Closed	-$35.2M	–	5
2021 Q3	$35.2M	Hold	1,954,904	–	–	48.8%	1
2021 Q2	$34.3M	Hold	1,954,904	–	–	36.39%	1
2021 Q1	$49.3M	Buy	1,954,904 +334,660	+21%	+$6.54M	43.26%	1
2020 Q4	$10.5M	Buy	1,620,244 +935,332	+137%	+$3.95M	12.18%	6
2020 Q3	$1.76M	Buy	+684,912	New	+$1.53M	1.31%	9
2019 Q1	–	Sell	-265,694	Closed	-$1.96M	–	20
2018 Q4	$1.96M	Sell	265,694 -46,674	-15%	-$481K	0.64%	22
2018 Q3	$4.54M	Hold	312,368	–	–	1%	18
2018 Q2	$6.24M	Hold	312,368	–	–	1.34%	16
2018 Q1	$5.47M	Buy	312,368 +99,418	+47%	+$2.11M	1.19%	15
2017 Q4	$5.25M	Sell	212,950 -50,000	-19%	-$1.22M	1.47%	14
2017 Q3	$6.79M	Buy	+262,950	New	+$7.05M	1.87%	13
2017 Q2	–	Sell	-140,000	Closed	-$4.17M	–	27
2017 Q1	$4.17M	Sell	140,000 -15,767	-10%	-$455K	1.6%	14
2016 Q4	$4.23M	Buy	+155,767	New	+$3.97M	1.84%	13

Other funds holding ACRS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Foresite Capital Management III's ACRS Position: Q4 2021 in Review

Foresite Capital Management III sold out of Aclaris Therapeutics (ACRS) in Q4 2021, closing a stake of 1,954,904 shares — an estimated $35.2M sold.

Foresite Capital Management III first reported a position in ACRS in Q4 2016 and held it in 13 quarters. The position peaked at $49.3M in Q1 2021. 133 funds tracked by Wall St. Rank hold ACRS as of Q4 2021.

Foresite Capital Management III reported no remaining Aclaris Therapeutics position as of Q4 2021 after selling out during the quarter.
Foresite Capital Management III sold 1,954,904 Aclaris Therapeutics shares in Q4 2021, an estimated $35.2M.
Foresite Capital Management III first reported a position in Aclaris Therapeutics in Q4 2016 and held it in 13 quarters.
Foresite Capital Management III's Aclaris Therapeutics position peaked at $49.3M in Q1 2021.
133 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2021.

Based on Foresite Capital Management III's 13F filing for Q4 2021, filed 11 Feb 2022.